Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic. Eli Lilly announced the results on 28 October 2026. Retatrutide is investigational, so only Ozempic can be prescribed today.
What the Retatrutide vs Ozempic Trial Tested
The study is TRANSCEND-T2D-2 (NCT06260722). Lilly describes it in its press release as a randomised, open-label phase 3 trial. It enrolled 1,298 adults with type 2 diabetes. Their disease was inadequately controlled on metformin, with or without an SGLT2 inhibitor. Baseline A1C ranged from 7.0 to 10.5 per cent.
Participants were randomised 2:2:1 to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg. Retatrutide started at 2 mg. The dose rose every four weeks to its target. Treatment lasted 80 weeks. About 650 participants are continuing retatrutide for a further 24 weeks.
The primary objective was noninferiority. Lilly wanted to show retatrutide 12 mg matched Ozempic 2 mg on A1C at 80 weeks. Lilly calls it the first phase 3 trial comparing retatrutide with another incretin medicine. It also calls it the sixth phase 3 trial in which retatrutide has delivered “powerful efficacy”.
Efficacy: How Far Apart Were the Two Drugs?
A1C, the primary measure
All figures in Lilly’s release use the efficacy estimand. Baseline A1C averaged 8.3 per cent. A1C fell by 2.2 percentage points on both retatrutide doses. It fell by 1.8 points on Ozempic 2 mg.
Lilly says the primary and all key secondary endpoints were met. It reports that retatrutide 12 mg was superior to Ozempic on A1C (p<0.001). The 9 mg dose met noninferiority as a key secondary endpoint. Lilly describes the 9 mg superiority results on A1C and systolic blood pressure as nominal.
Body weight, a key secondary measure
Baseline body weight averaged 102.4 kg. Weight fell by 19.5 per cent (20.1 kg) on retatrutide 9 mg. It fell by 20.9 per cent (21.5 kg) on 12 mg. On Ozempic 2 mg it fell by 9.4 per cent (9.5 kg).
Lilly also reports larger improvements than Ozempic in non-HDL cholesterol, triglycerides and systolic blood pressure. This article does not report those figures. Weight loss was a key secondary goal, BioSpace reported, not the primary one.
How Do Retatrutide and Ozempic Differ?
Ozempic contains semaglutide, which acts on one target, the GLP-1 receptor. Retatrutide acts on three: GLP-1, GIP and glucagon. BioPharma Dive draws the same distinction. It adds that Lilly’s Mounjaro and Zepbound act on GLP-1 and GIP.
Regulatory status differs too. The UK Ozempic summary of product characteristics covers adults with “insufficiently controlled type 2 diabetes mellitus”. It frames use as an adjunct to diet and exercise. It says weekly doses above 2 mg are not recommended. The emc page was last updated on 28 July 2026.
Retatrutide has no licence anywhere. Lilly’s release says it has not been approved by the FDA or any regulatory organisation. A search of the emc on 29 October 2026 returned no retatrutide listing. Any product sold online under that name is therefore unlicensed.
Retatrutide vs Ozempic Side Effects: What the Trial Reported
Lilly says the majority of adverse events were mild to moderate. It says they typically resolved during treatment. The figures below are for retatrutide 9 mg, retatrutide 12 mg and Ozempic 2 mg, in that order.
Diarrhoea occurred in 28.3, 32.7 and 26.4 per cent. Nausea occurred in 21.2, 23.8 and 21.3 per cent. Vomiting occurred in 10.2, 15.0 and 13.2 per cent.
Some events were less common on retatrutide. Constipation occurred in 14.2, 13.1 and 19.8 per cent. Dyspepsia occurred in 10.4, 8.5 and 11.6 per cent. Urinary tract infection occurred in 5.8, 4.2 and 5.8 per cent.
Dysesthesia, which BioSpace describes as a prickling or burning sensation, occurred in 4.8, 6.5 and 2.7 per cent. Discontinuation because of adverse events was 4.8, 7.9 and 2.7 per cent. The 12 mg dose had the largest efficacy figures and the highest discontinuation rate.
The UK Ozempic SmPC lists nausea and diarrhoea among its very common adverse reactions. A review of Lilly’s release on 29 October 2026 found no hypoglycaemia figure for retatrutide. That silence is not a finding that none occurred.
What the Retatrutide vs Ozempic Comparison Does Not Show
The trial was open-label, so participants and investigators knew which drug was in use. Lilly’s release reports the efficacy estimand only. That estimand describes outcomes in people who stay on treatment. A treatment-regimen estimand, which counts everyone randomised, was not reported.
Full results have not been presented or published. Lilly says they will appear at a future medical meeting and in a peer-reviewed journal. It gives no dates. Until then, the figures rest on a sponsor release.
The retatrutide vs Ozempic comparison is also one trial in one population. Participants had type 2 diabetes and were taking metformin. The results say little about people without diabetes. They say little about other background treatments.
Dose choice also shapes the comparison. Lilly’s headline describes 2 mg as Ozempic’s highest approved dose. Retatrutide was titrated up to 9 mg or 12 mg. The trial does not test lower Ozempic doses.
When Could Retatrutide Be Approved?
Lilly’s release does not state that a submission has been made. BioSpace reports that Lilly plans to file for approval in the first quarter of 2027. Lilly had previously expected to file in 2026, BioSpace added. It gives no separate timeline for type 2 diabetes.
A separate question could affect the route. BioSpace reported on 5 August 2026 that Lilly and the FDA disagree over whether retatrutide is a biologic. The FDA’s position is that it is not a protein under its definition. On that view, Lilly would need a new drug application.
AJMC reported on 7 October 2026 that a court backed the FDA on the amino acid count in September 2025. It said the court set aside the FDA’s “analogous to a protein” finding. That question went back to the agency. Lilly has appealed. AJMC says the market timeline could slip if the FDA does not accept a biologics licence application.
The phase 3 TRIUMPH obesity data and the likely UK route are covered in earlier analysis. A monthly obesity drug tracker follows readouts and approval decisions.
What Would Settle the Retatrutide vs Ozempic Question?
Several milestones would sharpen the answer. The first is full data at a congress or in a journal, including the treatment-regimen estimand. The second is TRIUMPH-5, in which Lilly is comparing retatrutide head-to-head with tirzepatide. The third is a regulatory submission and any label wording that follows. Lilly’s release gives no date for any of them.
One analyst has offered a view. BioPharma Dive quoted David Risinger of Leerink from a client note. He said the results “strengthen the case for retatrutide’s long-term differentiation”. He forecasts annual retatrutide sales of $15 billion in 2032. BioPharma Dive gives Wall Street consensus as $10 billion. These are one analyst’s estimates, not verified figures.
For now, the verified answer on retatrutide vs Ozempic is narrow. In one sponsor-reported trial in type 2 diabetes, retatrutide lowered A1C and weight more than Ozempic 2 mg. Discontinuation was higher at 12 mg. Whether that holds in full data, and whether regulators agree, is not yet known.
